【摘要】：目的卡培他濱作為一線化療藥物,誘發(fā)手足綜合征(hand foot syndrome,HFS)的發(fā)病率高,但目前HFS的發(fā)病機(jī)制不清,臨床研究過程中相關(guān)標(biāo)本(尤其是病理標(biāo)本)難以獲得。本研究旨在建立理想卡培他濱誘導(dǎo)HFS大鼠模型,從而應(yīng)用于卡培他濱致HFS的發(fā)病機(jī)制及防治措施的研究中。方法 SD雌性大鼠115只,按實(shí)驗(yàn)需求分為A、B、C、D、E、F 6組,A組以200mg/kg卡培他濱灌胃連續(xù)7d,2次/d,休息3d。B組在A組基礎(chǔ)上再灌胃7d,建立卡培他濱誘導(dǎo)HFS大鼠模型,C組400mg/kg,灌胃連續(xù)7d,2次/d。D、E組為空白對(duì)照組,F組為正常對(duì)照組。通過圖像對(duì)比,HE染色和天狼猩紅染色等方法對(duì)比評(píng)價(jià)所建立HFS模型。結(jié)果 A組HFS發(fā)生率為40.0%,B組總發(fā)病率可達(dá)到77.5%,C組HFS發(fā)病率可達(dá)到80.0%,D、E、F組HFS發(fā)病率均為0。經(jīng)統(tǒng)計(jì)學(xué)分析,A組與B、C兩組相比HFS發(fā)病率差異有統(tǒng)計(jì)學(xué)意義,P0.001;B組與C組相比HFS發(fā)病率差異無統(tǒng)計(jì)學(xué)意義,P=1.000。但是,C組大鼠第1個(gè)周期平均體質(zhì)量(F=6.779 3,P0.001)與第2個(gè)周期平均體質(zhì)量(F=23.611 1,P0.001)均明顯低于B組。結(jié)論與200mg/kg卡培他濱灌胃,給藥2個(gè)周期相比,200 mg/kg卡培他濱灌胃給藥1個(gè)周期,HFS的發(fā)病率較低,而400mg/kg卡培他濱灌胃給藥2個(gè)周期,并不能增加造模成功率,而且增加了造模成本,引起不良反應(yīng)發(fā)生增加。因此,200mg/kg卡培他濱灌胃給藥2個(gè)周期的造模方法,在不增加造模成本的同時(shí),既保證了高的造模成功率(77.5%),也不會(huì)致模型大鼠出現(xiàn)嚴(yán)重的給藥不良反應(yīng),能夠建立質(zhì)量較高的卡培他濱誘導(dǎo)HFS的大鼠模型。
[Abstract]:Objective capecitabine, as a first-line chemotherapeutic drug, has a high incidence of (hand foot syndrome induced by (hand foot syndrome, but the pathogenesis of HFS is not clear, and it is difficult to obtain relevant specimens (especially pathological ones) in the course of clinical research. The purpose of this study was to establish an ideal capecitabine-induced HFS rat model and to apply it to the study of the pathogenesis and prevention and treatment of capecitabine-induced HFS. Methods 115 SD female rats, According to the experimental requirements, the rats were divided into two groups: group A: 200mg/kg capecitabine was perfused intragastrically twice a day for 7 consecutive days. The rest 3d.B group was reperfused on the basis of group A for 7 days. The rat model of capecitabine induced by capecitabine was established in group C (400mg / kg). The rats in group C received oral administration of capecitabine twice times for 7 days as control group. The control group was the normal control group. The HFS model was established by image contrast HE staining and sirius red staining. Results the incidence of HFS in group A was 40.0% and the total incidence of HFS in group B was 77.5%. The incidence of HFS in group C was 80.00.The incidence of HFS in group F was 0. The incidence of HFS in group A was significantly higher than that in group B (P 0.001). There was no significant difference in incidence of HFS between group B and group C (P = 1.000). However, the mean body weight of the first cycle (FV 6.779 3) and the second cycle (FN 23.611 1 / P0.001) in group C were significantly lower than those in group B (P 0.001), but the mean body mass of group C was significantly lower than that of group B (P 0.001). Conclusion compared with 200mg/kg capecitabine for 2 cycles, the incidence of 1 cycle of capecitabine administration is lower than that of 400mg/kg capecitabine for 2 cycles, which can not increase the success rate of model making and increase the cost of model making. The incidence of adverse reactions increased. Therefore, the model method of 200 mg / kg capecitabine for 2 cycles not only guaranteed a high success rate (77.5%), but also did not cause severe adverse drug reactions in model rats. The rat model of HFS induced by capecitabine with high quality was established.
【作者單位】： 河北北方學(xué)院研究生院;
【基金】：全軍“十二五”中醫(yī)藥重點(diǎn)項(xiàng)目(10ZYZ105) 河北省研究生創(chuàng)新資助項(xiàng)目(285)
【分類號(hào)】：R-332;R730.53
，

本文編號(hào)：2156204